Sujatha Gurunathan

Blog Post

How Expedited Drug Approval Impacts the Neuromuscular Disease Treatment Landscape

By Sujatha Gurunathan | February 4, 2021
Blog Post

Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatments

By Sujatha Gurunathan | November 17, 2020
Blog Post

Scholar Rock Announces Positive Results from Interim Analysis of TOPAZ Phase 2 Study of SRK-015 to Treat SMA

By Sujatha Gurunathan | October 28, 2020
Blog Post

Amylyx Announces More Results from Study of AMX0035 to Treat ALS

By Sujatha Gurunathan | October 19, 2020
Blog Post

FDA Accepts Sarepta Therapeutics’ New Drug Application for DMD Treatment Casimersen

By Sujatha Gurunathan | August 26, 2020
Blog Post

Biogen Announces Positive Results from Phase 1/2 Study of Tofersen to Treat a Genetic Form of ALS

By Sujatha Gurunathan | July 14, 2020
Blog Post

Sarepta Therapeutics Announces Positive Results from the SRP-9001 Gene Therapy Trial to Treat DMD

By Sujatha Gurunathan | June 22, 2020
Blog Post

Momenta Pharmaceuticals Announces Positive Results from Phase 2 Vivacity-MG Study of Nipocalimab for Treatment of Generalized Myasthenia Gravis

By Sujatha Gurunathan | June 18, 2020
Blog Post

Sarepta Therapeutics Announces Positive Results from the SRP-9003 Gene Therapy Trial to Treat LGMD2E

By Sujatha Gurunathan | June 11, 2020
Blog Post

ReveraGen BioPharma Announces Completion of Vamorolone Study in 41 DMD Patients

By Sujatha Gurunathan | June 8, 2020